Spin-offSpun off from AnaptysBioANABNasdaq
The two companies
Open either company's hub for its full SEC financials, ratios, ownership, filings, and every other event it's been part of.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- Nasdaq
- State of incorporation
- DE
- Record date
- April 6, 2026
- Distribution date
- April 20, 2026
- Ratio
- 1:1
- Parent sector
- Pharmaceutical Preparations
- Form
- 10-12B/A
- Filed
- March 27, 2026
Financials — parent vs spin-off
SEC XBRL · latest year- Revenue
- $235M
- Operating income
- $48M
- Net income
- −$13M
- Total assets
- $364M
- Equity
- $37M
No XBRL financials available.
Latest reported figures from each company's own SEC filings — the parent after the separation and the spin-off as a standalone. Full multi-year history on each company hub.
Spin-off signals
score 1/4 favorable · factors, not advice- Focus-increasingNo — both Healthcare
Spin-offs into a different sector than the parent (pure-plays) have historically outperformed diversifying ones.
- Tax-basis reportNone found
A Form 8937 (basis allocation) accompanies tax-free §355 spin-offs — favorable for taxable holders.
- Insider buying (post-spin)None recorded
Officers/directors buying their own newly independent shares (Form 4) has historically preceded outperformance.
- Time since spin-off1 month
Studies find the spin-off return premium concentrates in roughly the first one to three years.
Factors the spin-off research literature (Greenblatt; Cusatis-Miles-Woolridge; Desai-Jain) associates with outcomes — computed from this company's own SEC filings, shown as factors, not a recommendation. The premium is debated and not guaranteed. How we compute these ↗
Filings & documents
Every entry traces to SEC EDGAR. The Information Statement is the primary source; the links below open the full filing and each company's complete filing history.